Panacea and Apotex settle over Abraxane

Panacea Biotec and Apotex have secured a launch date for the firms’ generic Abraxane (protein-bound paclitaxel) 100mg/vial for injectable suspension in the US and other markets, under a patent-litigation settlement agreement with originator Celgene.